Using the self-administration of apomorphine and cocaine to measure the pharmacodynamic potencies and pharmacokinetics of competitive dopamine receptor antagonists

Journal of Neuroscience Methods

Volumn 194, Issue 2, 2011, Pages 252-258

  Norman, Andrew B ^a   Tabet, Michael R ^a   Norman, Mantana K ^a   Tsibulsky, Vladimir L ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Cmin; Equiactive agonist concentration; PA2; Pharmacodynamics; Pharmacokinetics; Satiety threshold; Schild analysis

Indexed keywords

8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE; APOMORPHINE; COCAINE; DOMPERIDONE; ETICLOPRIDE; OLANZAPINE; TRIFLUPROMAZINE;

ANIMAL EXPERIMENT; ARTICLE; DRUG EFFECT; DRUG ELIMINATION; DRUG MECHANISM; DRUG POTENCY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SATIETY;

ANIMALS; APOMORPHINE; BEHAVIOR, ANIMAL; COCAINE; CONDITIONING, OPERANT; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOPAMINE UPTAKE INHIBITORS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SELF ADMINISTRATION; TIME FACTORS;

EID: 78650513628     PISSN: 01650270     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jneumeth.2010.10.017     Document Type: Article

References (35)

1. Ahmed S.H., Koob G.F. Transition to drug addiction: a negative reinforcement model based on an allostatic decrease in reward function. Psychopharmacology 2005, 180:473-490.
2. Arunlakshana O., Schild H.O. Some quantitative uses of drug antagonists. Br J Pharmacol Chemother 1959, 14:47-58.
3. Barone J.A. Domperidone: a peripherally acting dopamine 2-receptor antagonist. Ann Pharmacother 1999, 33:429-440.
4. Baxter B.L., Gluckman M.I., Stein L., Scerni R.A. Self-injection of apomorphine in the rat: positive reinforcement by a dopamine receptor stimulant. Pharmacol Biochem Behav 1974, 2:387-391.
5. Bertalmio A.J., Woods J.H. Differentiation between mu and kappa receptor-mediated effects in opioid drug discrimination: apparent pA2 analysis. J Pharmacol Exp Ther 1987, 243:591-597.
6. Bertalmio A.J., Woods J.H. Reinforcing effect of alfentanil is mediated by mu opioid receptors: apparent pA2 analysis. J Pharmacol Exp Ther 1989, 251:455-460.
7. Booze R.M., Lehner A.F., Wallace D.R., Welch M.A., Mactutus C.F. Dose-response cocaine pharmacokinetics and metabolite profile following intravenous administration and arterial sampling in unanesthetized, freely moving male rats. Neurotoxicol Teratol 1997, 19:7-15.
8. Colquhoun D. Why the Schild method is better than Schild realized. Trends Pharmacol Sci 2007, 28:608-614.
9. Ettenberg A., Pettit H.O., Bloom F.E., Koob G.F. Heroin and cocaine intravenous self-administration in rats: mediation by separate neural systems. Psychopharmacology 1982, 78:204-209.
10. Farde L., Halldin C., Stone-Elander S., Sedvall G. PET analysis of human dopamine receptor subtypes using 11C-SCH 23390 and 11C-raclopride. Psychopharmacology 1987, 92:278-284.
11. Gifford A.N., Gatley S.J., Volkow N.D. Evaluation of the importance of rebinding to receptors in slowing the approach to equilibrium of high-affinity PET and SPECT radiotracers. Synapse 1998, 28:167-175.
12. Hietala J., Seppala T., Lappalainen J., Syvalahti E. Quantification of SCH 39166, a novel D1 dopamine receptor antagonist, in rat brain and blood. Psychopharmacology 1992, 106:455-458.
13. Kenakin T.P. Competitive antagonism. Pharmacologic analysis of drug-receptor interaction 1997, 331-373. Lippincott-Raven, Philadelphia, PA. Third edition. T. Kenakin (Ed.).
14. Kilts C.D., Dew K.L., Ely T.D., Mailman R.B. Quantification of R-(+)-7-chloro-8-hydroxy-1-phenyl-2,3,4,5-tetrahydro-1H-3-methyl-3-benzazepine in brain and blood by use of reversed-phase high-performance liquid chromatography with electrochemical detection. Biomed Appl 1985, 342:452-457.
15. Koob G.F., Le H.T., Creese I. The D1 dopamine receptor antagonist SCH 23390 increases cocaine self-administration in the rat. Neurosci Lett 1987, 79:315-320.
16. Melzacka M., Wiszniowska G., Daniel W., Vetulani J. Behavioral effects and cerebral pharmacokinetics of apomorphine in the rat: dependence upon the route of administration. Pol J Pharmacol Pharm 1979, 31:309-317.
17. Nicolaysen L.C., Pan H.T., Justice J.B. Extracellular cocaine and dopamine concentrations are linearly related in rat striatum. Brain Res 1988, 456:317-323.
18. Norman A.B., Tsibulsky V.L. The compulsion zone: a pharmacological theory of acquired cocaine self-administration. Brain Res 2006, 1116:143-152.
19. Paalzow L.K., Paalzow G.H. Concentration-response relations for apomorphine effects on heart rate in conscious rats. J Pharm Pharmacol 1986, 38:28-34.
20. Paronis C.A., Bergman J. Apparent pA2 values of benzodiazepine antagonists and partial agonists in monkeys. J Pharmacol Exp Ther 1999, 290:1222-1229.
21. Rang H.P. The receptor concept: pharmacology's big idea. Br J Pharmacol 2006, 147:S9-S16.
22. Richelson E., Nelson A. Antagonism by neuroleptics of neurotransmitter receptors of normal human brain in vitro. Eur J Pharmacol 1984, 103:197-204.
23. Roberts D.C.S., Vickers G. Atypical neuroleptics increase self-administration of cocaine: an evaluation of a behavioral screen for antipsychotic activity. Psychopharmacology 1984, 82:135-139.
24. Roberts D.C., Corcoran M.E., Fibiger H.C. On the role of ascending catecholaminergic systems in intravenous self-administration of cocaine. Pharmacol Biochem Behav 1977, 6:615-620.
25. Rowlett J.K., Wilcox K.M., Woolverton W.L. Self-administration of cocaine-heroin combinations by rhesus monkeys: antagonism by naltrexone. J Pharmaol Exp Ther 1998, 286:61-69.
26. Schild HO. pA, a new scale for the measurement of drug antagonism. Br J Pharmacol Chemother 1947, 2:189-206.
27. Schild H.O. Drug antagonism and pAx. Pharmacol Rev 1957, 9:242-246.
28. Seeman P. Dopamine D2 receptors as treatment targets in schizophrenia. Clin Schizophr Relat Psychoses 2010, 1:56-73.
29. Tsibulsky V.L., Norman A.B. Satiety threshold: a quantitative model of maintained cocaine self-administration. Brain Res 1999, 839:85-93.
30. Tsibulsky V.L., Norman A.B. Real time computation of in vivo drug levels during drug self-administration experiments. Brain Res Brain Res Protoc 2005, 15:38-45.
31. Wise R.A. Cognitive factors in addiction and nucleus accumbens function: some hints from rodent models. Psychobiology 1999, 27:300-310.
32. Woods J.H., Winger G., France C.P. Use of in vivo apparent pA2 analysis in assessment of opioid abuse liability. Trends Pharmacol Sci 1992, 13:282-286.
33. Yokel R.A., Pickens R. Drug level of d- and l-amphetamine during intravenous self-administration. Psychopharmacologia 1974, 34:255-264.
34. Yokel R.A., Wise R.A. Increased lever pressing for amphetamine after pimozide in rats: implications for a dopamine theory of reward. Science 1975, 187:547-549.
35. Yokel R.A., Wise R.A. Amphetamine-type reinforcement by dopaminergic agonists in the rat. Psychopharmacology 1978, 58:289-296.